Drug Profile
Research programme: CCR5 agonists - Ogeda
Alternative Names: ESN-196Latest Information Update: 18 May 2017
Price :
$50
*
At a glance
- Originator Euroscreen
- Developer Ogeda
- Class Small molecules
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
- 19 Oct 2016 Euroscreen is now called Ogeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in Belgium